R&D channel feed

Am­gen qui­et­ly kills an obe­si­ty pro­gram, cast­ing bleak fu­ture for once-promis­ing tar­get

4 years ago
Discovery

Open sea­son on PBMs but FTC votes against dig­ging in­to their an­ti-com­pet­i­tive prac­tices fur­ther

4 years ago

In­di­an man­u­fac­tur­er called out for rust and lack­lus­ter records; Span­ish CMO signs 10-year com­mit­ment to make mR­NA vac­cines

4 years ago

In­novent claims two PhI­II wins for PC­SK9 an­ti­body, but non-Chi­na strat­e­gy re­mains un­clear

4 years ago

As Omi­cron fears fade, pan­dem­ic re­stric­tions are be­ing dis­man­tled. And that's a big deal for some bio­phar­mas

4 years ago

Sage, Bio­gen tout an­oth­er PhI­II win for de­pres­sion pill, but dura­bil­i­ty con­cerns again cloud the drug's fu­ture

4 years ago

In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

4 years ago

With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

4 years ago

Pad­cev gets a shot at an­oth­er in­di­ca­tion — for in­va­sive blad­der can­cer — thanks to ini­tial da­ta read­out

4 years ago
Pharma

As­traZeneca/Mer­ck come out of AS­CO GU with a big win over J&J in bat­tle over prostate can­cer fran­chis­es

4 years ago

Cy­to­ki­net­ic­s' lat­est PhI­II study of ome­cam­tiv flops — kick­ing out an­oth­er leg from un­der the mar­ket case it was build­ing

4 years ago

Am­gen comes in sec­ond with its lat­est batch of KRAS da­ta, but its ri­val is still hav­ing prob­lems catch­ing up

4 years ago

Bavar­i­an Nordic lands break­through des­ig­na­tion for RSV vac­cine; Ucel­lo clos­es Se­ries A to ad­vance CAR-T ther­a­pies

4 years ago
News Briefing

Mod­er­na in fi­nal talks to build an mR­NA man­u­fac­tur­ing and R&D hub in the UK — re­port

4 years ago
Manufacturing

FDA post­pones ad­comm for Pfiz­er's Covid-19 vac­cine for the youngest age group

4 years ago
Coronavirus

Af­ter Lil­ly's sin­til­imab shel­lack­ing, Chi­na-on­ly on­col­o­gy tri­als are fac­ing a new — and un­fa­vor­able — re­al­i­ty at the FDA

4 years ago
China

In lat­est an­ti­sense fail­ure, Pro­QR's rare eye dis­ease treat­ment falls flat

4 years ago

Rich Hey­man-backed biotech gets out the axe as it sets course on sur­vival mis­sion

4 years ago

No­vavax says its vac­cine is 80% ef­fec­tive in teens, but man­u­fac­tur­ing ques­tions con­tin­ue to cloud fu­ture

4 years ago
Coronavirus

Af­ter a con­tentious lead-up, Rob Califf like­ly to be con­firmed as FDA com­mis­sion­er next week

4 years ago

At­las-backed neu­rol­o­gy play­er Arku­da reemerges from the grind­stone with a lead pro­gran­ulin drug ap­proach­ing the clin­ic

4 years ago

As­traZeneca picks win­ner in in­haled JAK 'bake-of­f' while sweep­ing Alex­ion drug out

4 years ago

In fi­nal analy­sis, J&J's un­der­dog vac­cine of­fers on­ly 52.9% pro­tec­tion against Covid-19

4 years ago
Coronavirus

Hal Bar­ron’s swan song as GSK R&D chief ends with a promise: The best is yet to come

4 years ago
First page Previous page 146147148149150151152 Next page Last page
A service from the Financial Times